AbCellera Biologics Q4 2023 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $9.18M Beat $8.88M Estimate
Portfolio Pulse from Benzinga Newsdesk
AbCellera Biologics reported Q4 2023 earnings with a GAAP EPS of $(0.17), missing the $(0.13) estimate, but sales of $9.18M exceeded the $8.88M forecast. This represents a 57.40% decrease in sales compared to the same period last year.
February 20, 2024 | 9:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbCellera Biologics reported a Q4 2023 GAAP EPS of $(0.17), missing estimates, but exceeded sales forecasts with $9.18M. Year-over-year sales dropped by 57.40%.
The missed EPS estimate is likely to negatively impact investor sentiment in the short term, despite the slight beat on sales forecasts. The significant year-over-year decrease in sales further compounds concerns about the company's growth trajectory and profitability, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100